Abstract
Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have